Organon & Co. filed a Form 10-Q for the quarter ended September 30, 2026, furnishing supplemental non-GAAP financial metrics in lieu of its customary earnings press release due to its pending merger with Sun Pharmaceutical Industries Limited. The company reported GAAP diluted earnings per share of $0.60 and net income of $164 million for the quarter. Adjusted metrics included adjusted net income of $256 million, adjusted diluted EPS of $0.94, and adjusted EBITDA of $502 million. For the nine-month period, GAAP diluted EPS was $1.56 with net income of $418 million, while adjusted diluted EPS stood at $2.51 and adjusted EBITDA reached $1.378 billion. Organon & Co. operates in the pharmaceutical industry.
